Galimedix, Inc. | WebDisclosure

PRESS RELEASE

published on 05/06/2025 at 14:00, 10 months 28 days ago

Galimedix Therapeutics completes single ascending dose part of Phase 1 study with oral small molecule, GAL-101, an amyloid beta aggregation modulator
Galimedix Therapeutics completes single ascending dose of Phase 1 study with oral small molecule GAL-101 targeting amyloid beta aggregation modulator, supporting oral administration route. Next study arms and indications revealed

Galimedix Therapeutics GAL-101 Oral Administration Phase 1 Study Amyloid Beta
BRIEF

published on 04/01/2025 at 09:05, 1 year ago

Galimedix Reports Promising Data for Alzheimer's Treatment

Alzheimer's Disease GAL-201 Galimedix Therapeutics Neuroinflammation Amyloid-β Aggregation
BRIEF

published on 04/01/2025 at 09:05, 1 year ago

Galimedix publie des données prometteuses pour le traitement de la maladie d'Alzheimer

GAL-201 Maladie D'Alzheimer Galimedix Therapeutics Neuroinflammation Agrégation De L'amyloïde-β
PRESS RELEASE

published on 04/01/2025 at 09:00, 1 year ago

Galimedix Therapeutics presents further scientific data showing disease-modifying potential of oral GAL-201 in Alzheimer’s disease as well as beneficial effects on synaptic function and neuroimmunomod
Galimedix Therapeutics presents new preclinical data on GAL-201 at AD/PD 2025, showing promise in Alzheimer’s disease treatment by targeting misfolded Aβ monomers and reducing Aβ plaques with anti-inflammatory effects

Alzheimer's Disease Preclinical Data GAL-201 Galimedix Therapeutics Neuroinflammation
BRIEF

published on 03/24/2025 at 15:12, 1 year ago

Galimedix Therapeutics présente un traitement préclinique prometteur contre la maladie d'Alzheimer

Galimedix Therapeutics Neuroprotection Données Précliniques Traitement De La Maladie D'Alzheimer Bêta-amyloïde
BRIEF

published on 03/24/2025 at 15:12, 1 year ago

Galimedix Therapeutics to Present Promising Preclinical Alzheimer’s Treatment

Preclinical Data Galimedix Therapeutics Neuroprotection Alzheimer's Treatment Amyloid-beta
PRESS RELEASE

published on 03/24/2025 at 15:07, 1 year ago

Galimedix Therapeutics to present positive pre-clinical data with amyloid beta aggregation modulator in development for oral Alzheimer’s disease treatment at AD/PD™ 2025 Conference
Galimedix Therapeutics to present positive pre-clinical data with amyloid beta aggregation modulator for oral Alzheimer's disease treatment at AD/PD(TM) 2025 Conference

Alzheimer's Disease Galimedix Therapeutics Pre-clinical Data AD/PD 2025 Conference Aβ Aggregation Modulator
BRIEF

published on 12/23/2024 at 17:35, 1 year 3 months ago

Galimedix débute un essai de phase 2 avec les gouttes ophtalmiques GAL-101 pour la DMLA sèche

Étude De Phase 2 Neuroprotection GAL-101 DMLA Sèche Atrophie Géographique
BRIEF

published on 12/23/2024 at 17:35, 1 year 3 months ago

Galimedix Begins Phase 2 Trial with GAL-101 Eye Drops for Dry AMD

Phase 2 Study Neuroprotection GAL-101 Dry AMD Geographic Atrophy
PRESS RELEASE

published on 12/23/2024 at 17:30, 1 year 3 months ago

Galimedix Therapeutics initiates pivotal Phase 2 study with GAL-101 eye drops in dry AMD
Galimedix Therapeutics initiates Phase 2 study with GAL-101 eye drops for dry AMD, aiming to slow geographic atrophy growth. Trial led by world-leading retina experts and funded by Théa Open Innovation

Galimedix Therapeutics Phase 2 Study GAL-101 Dry AMD Geographic Atrophy

Published on 04/02/2026 at 22:00, 16 hours 31 minutes ago

Star Copper Announces Closing of Charity Flow-Through Unit Private Placement
Published on 04/02/2026 at 18:32, 19 hours 59 minutes ago

Datavault AI CEO Nathaniel Bradley to Present DataValue(R), DataScore(R), and Information Data Exchange(R) Technologies at XRP Tokyo 2026
Published on 04/02/2026 at 15:00, 23 hours 31 minutes ago

Jaguar Health Family Company Napo Pharmaceuticals Co-Sponsoring Pediatric Gastroenterology Conference: Elite Ped-GI Congress
Published on 04/02/2026 at 14:40, 23 hours 51 minutes ago

Northfield Capital Completes Acquisition Of Additional Interest In Juno Corp. And Announces Issuance Of Class B Multiple Voting Shares
Published on 04/02/2026 at 14:30, 1 day ago

Worksport Announces COR(TM) Portable Energy System Is Now Fully Certified, Including Key UL and CSA Approvals, for North American Retail and Commercial Distribution

View all ACCESSWIRE

Published on 04/03/2026 at 14:05, 26 minutes ago

AIRSEEKERS Tron and Tron SE Series Now Available: Redefining "Real Mowing" with FlowCut™ Technology
Published on 04/03/2026 at 11:47, 2 hours 44 minutes ago

EUROPLASMA: Information relative au nombre total de droits de vote et d’actions composant le capital au 31 mars 2026
Published on 04/03/2026 at 11:05, 3 hours 26 minutes ago

Hoymiles Bolsters European Plug-in Solar & Storage Market with HiFlow & HiFlow Pro Microinverters
Published on 04/03/2026 at 10:20, 4 hours 11 minutes ago

McDonald's Türkiye Introduces 'Archie' for Gamers
Published on 04/03/2026 at 08:55, 5 hours 36 minutes ago

EPH Group AG Secures Premium Resort Project in Vorarlberg

View all EQS

Published on 04/03/2026 at 13:29, 1 hour 2 minutes ago

Total number of voting rights and shares making up the share capital at March 31, 2026
Published on 04/03/2026 at 13:29, 1 hour 2 minutes ago

Capital et droits de vote au 31 mars 2026
Published on 04/03/2026 at 12:57, 1 hour 34 minutes ago

Mersen: Number of shares and voting rights as of March 31, 2026
Published on 04/03/2026 at 12:57, 1 hour 34 minutes ago

Mersen : nombre d'actions et de droits de vote au 31 mars 2026
Published on 04/02/2026 at 18:39, 19 hours 52 minutes ago

Mersen: Disclosure of trading own shares

View all LES ECHOS COMFI WIRE

News